Browsing Tag
InflaRx N.V.
2 posts
Why complement pathway competition in renal disease is intensifying around oral C5aR therapies
InflaRx N.V. is expanding izicopan across renal diseases as complement therapy competition intensifies. Discover what this means for nephrology markets.
InflaRx prepares for key INF904 Phase 2a topline readout in chronic skin inflammation trials
Find out how InflaRx’s INF904 topline Phase 2a data could redefine treatment for hidradenitis suppurativa and chronic spontaneous urticaria.